Showing results (1-10 of 177) with videos related to
Sort By:
Pageof 18
Acta Paediatrica (Oslo, Norway : 1992)|May 28, 2008
CNS-directed gene therapy for lysosomal storage diseasesMark S Sands, Mark E HaskinsMolecular Therapy : the Journal of the American Society of Gene Therapy|July 6, 2004
In vivo transduction of hematopoietic stem cells after neonatal intravenous injection of an amphotropic retroviral vector in miceLingfei Xu, Tom O'Malley, Mark S Sands, et al.Molecular Therapy : the Journal of the American Society of Gene Therapy|December 25, 2002
Evaluation of pathological manifestations of disease in mucopolysaccharidosis VII mice after neonatal hepatic gene therapyLingfei Xu, Robert L Mango, Mark S Sands, et al.Molecular Genetics and Metabolism|April 28, 2004
Neonatal retroviral vector-mediated hepatic gene therapy reduces bone, joint, and cartilage disease in mucopolysaccharidosis VII mice and dogsRobert L Mango, Lingfei Xu, Mark S Sands, et al.Acta Paediatrica (Oslo, Norway : 1992)|March 30, 2007
Animal models for mucopolysaccharidosis disorders and their clinical relevanceMark E HaskinsMethods in Molecular Biology (Clifton, N.J.)|October 29, 2011
AAV-mediated liver-directed gene therapyMark S SandsPediatric Endocrinology Reviews : PER|October 28, 2014
Mucopolysaccharidosis type VII: A powerful experimental system and therapeutic challengeMark S SandsJournal of Child Neurology|September 10, 2013
Considerations for the treatment of infantile neuronal ceroid lipofuscinosis (infantile Batten disease)Mark S SandsExpert Opinion on Biological Therapy|August 31, 2007
Gene therapy for mucopolysaccharidosisKatherine P Ponder, Mark E HaskinsBiochemical Society Transactions|September 19, 2014
Astrocytosis in infantile neuronal ceroid lipofuscinosis: friend or foe?Charles Shyng, Mark S SandsPageof 18